Kees de Joncheere

Cost–effectiveness thresholds: pros and cons

Melanie Bertram, Jeremy A. Lauer, Kees de Joncheere et al. · Bulletin of the World Health Organization · 2016 · 788 citations · Full text

Pharmacy, Economics, Health Policy +17

Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis

Swathi Iyengar, Kiu Tay-Teo, Sabine Vogler et al. · PLoS Medicine · 2016 · 246 citations · Full text

Social Sciences, Economics, Pharmacoeconomics +17

Differences in external price referencing in Europe—A descriptive overview

Christine Leopold, Sabine Vogler, A.K. Mantel-Teeuwisse et al. · Health Policy · 2011 · 136 citations

Business, Business Economics, Economics +11

Pharmaceutical policies in European countries in response to the global financial crisis

Sabine Vogler, Nina Zimmermann, Christine Leopold et al. · Southern Med Review · 2011 · 136 citations

Pharmacy, Pharmaceutical Policy, Fiscal Policy +13

Medicines availability for non-communicable diseases: the case for standardized monitoring

Jane Robertson, Cécile Macé, Gilles Forte et al. · Globalization and Health · 2015 · 55 citations · Full text

Pharmacy, Health Policy, Pharmaceutical Policy +16